65 reports of this reaction
2.1% of all SODIUM POLYSTYRENE SULFONATE reports
#10 most reported adverse reaction
END STAGE RENAL DISEASE is the #10 most commonly reported adverse reaction for SODIUM POLYSTYRENE SULFONATE, manufactured by ANI Pharmaceuticals, Inc.. There are 65 FDA adverse event reports linking SODIUM POLYSTYRENE SULFONATE to END STAGE RENAL DISEASE. This represents approximately 2.1% of all 3,148 adverse event reports for this drug.
Patients taking SODIUM POLYSTYRENE SULFONATE who experience end stage renal disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
END STAGE RENAL DISEASE is a less commonly reported adverse event for SODIUM POLYSTYRENE SULFONATE, but still significant enough to appear in the safety profile.
In addition to end stage renal disease, the following adverse reactions have been reported for SODIUM POLYSTYRENE SULFONATE:
The following drugs have also been linked to end stage renal disease in FDA adverse event reports:
END STAGE RENAL DISEASE has been reported as an adverse event in 65 FDA reports for SODIUM POLYSTYRENE SULFONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
END STAGE RENAL DISEASE accounts for approximately 2.1% of all adverse event reports for SODIUM POLYSTYRENE SULFONATE, making it a notable side effect.
If you experience end stage renal disease while taking SODIUM POLYSTYRENE SULFONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.